Evidence map›Paper›PMID 40454436›Full record

ArticleJournal of proteome research2025

Pairwise Attention: Leveraging Mass Differences to Enhance De Novo Sequencing of Mass Spectra.

Joel Lapin, Alfred Nilsson, Mathias Wilhelm, Lukas Käll

Abstract read
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joel LapinComputational Mass Spectrometry, TUM School of Life Sciences, Technical University of Munich, 85354 Freising, Germany.
Alfred NilssonScience for Life Laboratory, KTH - Royal Institute of Technology, 171 65 Solna, Sweden.
Mathias WilhelmComputational Mass Spectrometry, TUM School of Life Sciences, Technical University of Munich, 85354 Freising, Germany.ORCID 0000-0002-9224-3258
Lukas KällScience for Life Laboratory, KTH - Royal Institute of Technology, 171 65 Solna, Sweden.ORCID 0000-0001-5689-9797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A fundamental challenge in mass spectrometry-based proteomics is determining which peptide generated a given MS2 spectrum. Peptide sequencing typically relies on matching spectra against a known sequence database, which in some applications is not available. Deep learning-based de novo sequencing can address this limitation by directly predicting peptide sequences from MS2 data. We have seen the application of the transformer architecture to de novo sequencing produce state-of-the-art results on the so-called nine-species benchmark. In this study, we propose an improved transformer encoder inspired by the heuristics used in the manual interpretation of spectra. We modify the attention mechanism with a learned bias based on pairwise mass differences, termed Pairwise Attention (PA). Adding PA improves average peptide precision at 100% coverage by 12.7% (5.9 percentage points) over our base transformer on the original nine-species benchmark. We have also achieved a 7.4% increase over the previously published model Casanovo. Our MS2 encoding strategy is largely orthogonal to other transformer-based models encoding MS2 spectra, enabling straightforward integration into existing deep-learning approaches. Our results show that integrating domain-specific knowledge into transformers boosts de novo sequencing performance.

Indexed as

Deep LearningMass SpectrometryPeptidesProteomicsSequence Analysis, ProteinAlgorithmsDatabases, ProteinTandem Mass SpectrometryPeptidesAttentionDe novo sequencingMass spectrometryMS2ProteomicsTransformers

Identifiers

PMID40454436
PMCPMC12235698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.